ADARx Pharmaceuticals, Inc. Common Stock (ADRX) stock: key figures, P/E, revenue and dividend

Health Care · United States

Price
17.95 USD
Market cap
1.83 bn USD
P/E (2025)
–
P/S (2025)
531.90
Dividend yield
0.00 %
Net margin
-2,119.11 %
Return on equity (ROE)
36.14 %
Return on assets (ROA)
-14.40 %

ADARx Pharmaceuticals, Inc. Common Stock financials

Fiscal year20242025
Revenue0.00 USD3.45 m USD
Operating income-58.23 m USD-88.37 m USD
EBIT-58.23 m USD-88.37 m USD
Net income-46.36 m USD-73.09 m USD
Diluted EPS – continuing operations-0.45 USD-0.72 USD

Full history since 2024, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About ADARx Pharmaceuticals, Inc. Common Stock

ADARx Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on developing siRNA therapeutics to treat a broad spectrum of diseases. The company offers hepatic-targeted programs, including Agazisiran, a complement factor B (CFB) program that represents a pipeline-in-a-product opportunity, where a single therapeutic candidate has the potential to address multiple indications; Onvuzosiran, a clinical program for the prevention of HAE attacks; and ADX-626, a Factor XI (FXI) program for secondary stroke prevention with additional clinical potential for stroke prevention in atrial fibrillation. It also offers extrahepatic-targeted programs, such as ADX-077, an adipose-targeted obesity program designed to reduce body weight and fat while preserving lean mass; and ADX-199, a neuron-targeted program designed to selectively silence and degrade amyloid-ß precursor protein (APP) mRNA in neurons, which is genetically linked to Alzheimer's disease. The company was incorporated in 2019 and is based in San Diego, California.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 28.10.2026. Details in the risk notice.